Bausch Health Companies Inc. · TSX:BHC
Bausch Health Companies — Valeant Pharmaceuticals International — Shareholder Meeting (May 2015)
22 slides from Bausch Health Companies's shareholder meeting presentation, May 19, 2015
Slide 1: Valeant Pharmaceuticals International, Inc. 2015 Annual Meeting
Valeant Pharmaceuticals International, Inc. 2015 Annual Meeting May 19, 2015 Laval, Quebec, Canada
Slide 2: Introductions
Introductions Board of Directors Executive Management Ronald Farmer Robert Chai-Onn Colleen Goggins Dr. Ari Kellen Robert Ingram (Lead Director) Laizer Kornwasser Anders Lönner Dr. Pavel Mirovsky Theo Melas-Kyriazi Brian Stolz Robert Power Anne Whitaker Norma Provencio
Slide 3: Valeant Pharmaceuticals International, Inc. 2015 Annual Meeting
Valeant Pharmaceuticals International, Inc. 2015 Annual Meeting May 19, 2015 Laval, Quebec, Canada
Slide 4: Shareholder Voting Results
Shareholder Voting Results All Directors >90% Say on Pay (Executive >90% Compensation) PricewaterhouseCoopers >90% as Auditors 4
Slide 5: Valeant Pharmaceuticals International, Inc. 2015 Annual Meeting
Valeant Pharmaceuticals International, Inc. 2015 Annual Meeting May 19, 2015 Laval, Quebec, Canada
Slide 6: Forward-looking Statements
Forward-looking Statements Certain statements made in this presentation may constitute forward-looking statements, including, but not limited to, statements regarding the timing of and outcome of regulatory approvals and commercial plans with respect to product candidates and product launches, fut
Slide 7: Who Is Valeant?
Who Is Valeant? Focused, multinational specialty pharmaceutical company $75B+ Market Cap Headquartered in Laval, Quebec, Canada (NYSE/TSX: VRX) Unconventional Business Model Decentralized operating model Geographical and product diversity Focus on faster-growing geographies and therape
Slide 8: Highly Diversified Business Portfolio
Highly Diversified Business Portfolio Based on pro forma 2015 revenues excluding effect of inventory By Geography By Business Canada / Latin America BGx/Gx Australia 6% 4% Western 9% Devices 1 Europe 8% 14% Asia 8% 15% OTC / 62% Emerging United Solutions Europe, States Rx Africa, & 64% Middle East 1
Slide 9: Salix at a Glance
Salix at a Glance Mid-sized specialty pharma company that is a clear leader in the GI market Ranked #1 GI sales force 3 of the past 4 years(a) Traveler’s Diarrhea & Hepatic Encephalopathy (HE) Xifaxan: Approved for Hepatic Encephalopathy (HE) and Traveler’s Diarrhea PDUFA date for IBS-D –
Slide 10: Valeant's Approach to Innovation
Valeant’s Approach to Innovation Innovation critical to the industry and to Valeant We source innovation through our internal R&D, acquisitions, in- licensing We have acquired terrific set of capabilities and technologies over time Dow (Dermatology Rx and OTC) Bausch + Lomb (e.g., Contact
Slide 11: Key R&D Milestones for 2015
Key R&D Milestones for 2015 Product Category Action Status Additional studies requested EnVista Toric Eye Health File PMA 1H 2015 To Be Filed mid- 2016 Luminesse™ Eye Health File NDA 1H 2015 Filed NDA in March (Brimonidine) Vesneo (glaucoma) Eye Health File NDA 1H 2015 On Track Lotemax Gel Next Gen
Slide 12: Dermatology Launch Products
Dermatology Launch Products Leading branded product for onychomycosis among dermatologists and podiatrists Current sales annualizing at >$400M Recently launched 8 ml bottle; strong uptake Weekly TRx’s up 100% YTD New DTC campaign driving further growth Continued franchise growth with sal
Slide 13: Jublia TRx Growth Since Launch
Jublia TRx Growth Since Launch TRxs 30,000 • 1Q 2015 sales >$60 million ~25,000 25,000 • Annualized run rate >$400 million 20,000 DTC TV 15,000 10,000 5,000 0 13
Slide 14: Luzu TRx Growth 2015
Luzu TRx Growth 2015 TRxs 2,200 2,038 2,000 1,800 1,600 1,400 1,200 1,000 800 14
Slide 15: Onexton TRx Growth Since Launch
Onexton TRx Growth Since Launch TRxs Annualized run rate >$75 million 7,000 5,946 6,000 5,000 4,000 3,000 2,000 1,000 0 1/9 1/16 1/23 1/30 2/6 2/13 2/20 2/27 3/6 3/13 3/20 3/27 4/3 4/10 4/17 4/24 5/8 15
Slide 16: Ex-U.S. Launches
Ex-U.S. Launches Strong launch in Canada Surpassed generic Lamisil and is now the number 1 prescribed product for onychomycosis Launched in Sweden, UK, and Germany Ongoing registrations around the world Achieved 25% share in Sweden in less than one year Branded Gx 200+ launches across EM
Slide 17: Contact Lens Launch Products
Contact Lens Launch Products Continuing to sell to capacity First full manufacturing line installed and validated, producing commercial product 2nd commercial line expected in Q3 2015 Selected Ex-US launches planned for 2H 2015 Multifocal and Toric offerings approved, expected to launch in
Slide 18: U.S. Consumer Launch Products
U.S. Consumer Launch Products Continued expansion of the franchise with 9 launches planned in 2015 26% Y/Y growth in 2014 44% Y/Y growth in Q1, 2015 Expected to achieve revenues ~$150MM in 2015 Fastest growing product in category 18%+ growth Y/Y, ~17% market share Brand growing 20%, dr
Slide 19: Salix Late Stage Pipeline and Launch Products
Salix Late Stage Pipeline and Launch Products May 28th PDUFA date for IBS-D Currently in labeling discussions with FDA Launched Q4, 2014 Only recombinant product available for HAE Continued strong sales uptake Uceris tablets launched February 2013 Foam launch expected Q3/4 2015 Expec
Slide 20: 2015 - Validation of Valeant's Business Model
2015 - Validation of Valeant’s Business Model Robust organic growth profile Double-digit organic growth expected in 2015, 2016 and continued strong growth beyond Geographical and product diversification creates lower-risk profile Durable product portfolio limits patent expiry exposure Rich
Slide 21: Valeant's Execution Track Record
Valeant’s Execution Track Record Valeant Management Team Performance* USD $250 $200 >3,000% price adjusted increase in $150 VRX share price (Feb 2008 to today) $100 Consistently exceeded expectations $50 $0 2008 2009 2010 2011 2012 2013 2014 2015 VRX *Adjusted for Valeant/Biovail merger. 21
Slide 22: Valeant Pharmaceuticals International, Inc. 2015 Annual Meeting
Valeant Pharmaceuticals International, Inc. 2015 Annual Meeting May 19, 2015 Laval, Quebec, Canada
Valeant Pharmaceuticals International — Shareholder Meeting (May 2015) on 6ix